CD8A and gastric cancer: Interestingly, we find the stroma ratio is significantly lower in 5-FU-benefit diffuse samples compared to this in 5-FU-benefit intestinal samples, and the ratios of most immune components (Myeloid/M1.Macrophage/Tcell/CD8.Effector/CD8.Tem/NK.T/NK/Bcell/PlasmaB/NaiveB) are higher (although not significant) in 5-FU-benefit diffuse samples compared to these in 5-FU-benefit intestinal samples, suggesting a more depleted ECM and more enhanced immune process in 5-FU-benefit diffuse samples, which might explain the better performance of 5-FU on diffuse GC patients (Table 1).